Table 3.

Progression of ALSFRS-R and FVC% in treated with ALCAR 3 g/day and not treated

Group	Time	ALSFRS-R				FVC
		Estimatea	95% lower CL	95% upper CL	p value	Estimatea	95% lower CL	95% upper CL	p value
Treated with ALCAR 3 g/day	Month 0	42.2	39.5	44.8		98.6	88.5	108.7
	Month 4	37.1	34.2	39.9		88.2	78.0	98.4
	Month 8	32.0	28.5	35.4		77.8	66.5	89.2
	Month 12	26.9	22.6	31.2		67.4	54.2	80.7
	Month 18	19.2	13.4	25.0		51.8	34.8	68.8
	Month 24	11.5	4.2	18.9		36.2	14.9	57.6
	Slope	− 1.3	− 1.6	− 1.0	< 0.0001	− 2.6	− 3.4	− 1.8	< 0.0001
Not treated	Month 0	43.4	41.0	45.8		101.4	92.5	110.2
	Month 4	38.2	35.6	40.7		88.2	79.3	97.2
	Month 8	33.0	29.7	36.2		75.1	64.7	85.5
	Month 12	27.7	23.6	31.9		61.9	49.2	74.7
	Month 18	19.9	14.3	25.6		42.2	25.2	59.3
	Month 24	12.1	4.8	19.4		22.5	0.6	44.4
	Slope	− 1.3	− 1.6	− 1.0	< 0.0001	− 3.3	− 4.2	− 2.4	< 0.0001
Treated with ALCAR 3 g/day vs. not treated (difference)	Month 0	− 1.2	− 2.9	0.5		− 2.8	− 9.7	4.1
	Month 4	− 1.1	− 3.4	1.1		0.0	− 7.3	7.3
	Month 8	− 1.0	− 4.6	2.5		2.7	− 7.6	13.1
	Month 12	− 0.9	− 6.0	4.2		5.5	− 9.0	20.0
	Month 18	− 0.7	− 8.2	6.8		9.6	− 11.8	31.0
	Month 24	− 0.5	− 10.5	9.4		13.7	− 14.8	42.2
	Slope	0.0	− 0.4	0.4	0.8910	0.7	− 0.6	1.9	0.2747

ALCAR acetyl-l-carnitine, FVC forced vital capacity, ALSFRS-R amyotrophic lateral sclerosis functional rating scale-revised, CL confidence limit

^aMatched by age (± 5 years), sex, disease duration (± 3 years), site of onset; adjusted by riluzole use, EL Escorial category, progression rate category